General Actions (Not specific medical benefits for the user)
| Core Action | Mechanism |
| Enhances Insulin Response (Linagliptin) | The Linagliptin component inhibits the DPP-4 enzyme, preventing the breakdown of incretin hormones. This increases insulin secretion and reduces glucose production in a glucose-dependent manner. |
| Reduces Glucose Production (Metformin) | The Metformin component primarily acts on the liver to decrease the production of glucose (gluconeogenesis) and improves how muscle cells use sugar. |
| Improves Insulin Sensitivity | Metformin helps address the underlying insulin resistance, making the body's existing insulin (and any injected insulin) work more efficiently. |
| Comprehensive Glycemic Control | The combination targets multiple pathways, effectively lowering both fasting and post-meal blood sugar levels to help patients reach their overall blood sugar goals. |
⚠️ Important Safety Note:
Linaglip-M 2.5/850mg Tablet is a prescription anti-diabetic medication.
Warning! You must be logged in to submit a review.
Login
Customer questions & answers
Customer reviews
0 out of 5